Skip to content
Sharism- Lifestyle
Author:
Abbisko
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
July 1, 2026
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
June 23, 2026